AQP4 and myeloid sarcoma: Some clinically used biomarkers, such as serum aquaporin four antibodies (AQP4-IgG), which are used to differentiate between patients with MS and patients with neuromyelitis optica, have a median sensitivity of 62.3% with a range between 12.5 and 100%, depending on the assay used for the measurements (44).